On this page
- TL;DR
- Thyroid cancer VA rating criteria (DC 7914)
- Hypothyroidism after thyroid cancer: the DC 7903 rating
- Thyroid cancer residuals worth documenting
- How to prove thyroid cancer is service connected
- Why VA denies thyroid cancer claims
- Questions veterans ask about thyroid cancer
- What is the VA rating for thyroid cancer?
- Is thyroid cancer presumptive under the PACT Act?
- Is thyroid cancer presumptive for Agent Orange?
- What is the VA rating for hypothyroidism after a thyroidectomy?
- Is thyroid cancer presumptive for radiation exposure?
- Can I get a separate VA rating for a thyroidectomy scar?
- Bottom Line
- Related Conditions and Tools
- Sources and limits
Thyroid cancer is rated at 100 percent under 38 CFR § 4.119, Diagnostic Code 7914, malignant neoplasm of any specified part of the endocrine system. That much is well covered elsewhere.
What is not well covered is what happens next. The 100 percent does not last, the examination that ends it is mandatory rather than discretionary, and the hypothyroidism code that nearly every treated veteran lands on is itself time-limited. I see the same wrong assumption repeated across the search results for this condition: that lifelong thyroid hormone replacement holds a 30 percent rating indefinitely. Under the criteria in force since December 10, 2017, it does not. The other gap is service connection: for veterans who served in the countries the PACT Act covers, on or after August 2, 1990 or September 11, 2001 depending on the country, VA treats thyroid cancer as a neck cancer, which the law presumes.
TL;DR
- DC 7914 assigns 100 percent for a malignant endocrine neoplasm, including thyroid cancer.
- The 100 percent continues beyond the end of surgery, radioiodine, chemotherapy, or other treatment.
- Six months after treatment stops, a mandatory VA examination sets the new evaluation.
- Any reduction from that examination must follow 38 CFR § 3.105(e), which requires notice and a chance to respond.
- If there is no local recurrence or metastasis, VA rates residuals.
- The usual residual is hypothyroidism under DC 7903. Its 30 percent level runs for six months after initial diagnosis, then VA rates residual effects under their own body-system codes.
- Being on levothyroxine is not a rating criterion at any level of DC 7903.
- Thyroid cancer is on the radiation-exposed veteran presumptive list at 38 CFR § 3.309(d)(2)(ii).
- For a covered veteran under the PACT Act, VA's claims guidance counts thyroid cancer as a neck cancer, which 38 USC § 1120 presumes. Thyroid cancer is not on the Agent Orange or Camp Lejeune lists.
- Across 563 decided Board rulings on thyroid cancer from 2021 to 2026, 31.3% were granted, 18.7% denied and 50.1% remanded. The grant rate is 6.6 points above the Board-wide 24.7 percent, and remand is the most common outcome.
Thyroid cancer VA rating criteria (DC 7914)
DC 7914 covers malignant neoplasms of any specified part of the endocrine system. Papillary, follicular, medullary, and anaplastic thyroid carcinoma all fall inside it. The percentage does not vary by cell type, stage, or treatment intensity while the code applies.
The note attached to DC 7914 controls the timing.
A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination.
Three things follow from that sentence. The clock starts when treatment stops, not when the cancer is declared in remission. The examination is mandatory, so VA is obligated to schedule it. And the evaluation that comes out of it is a new rating decision, subject to § 3.105(e) if it lowers your percentage.
There is a related code worth knowing. DC 7919 covers C-cell hyperplasia of the thyroid. If antineoplastic therapy is required, VA evaluates it as a malignant neoplasm under DC 7914. If a prophylactic thyroidectomy is performed based on genetic testing and antineoplastic therapy is not required, VA evaluates it as hypothyroidism under DC 7903 instead.
Hypothyroidism after thyroid cancer: the DC 7903 rating
If there has been no local recurrence or metastasis, VA rates on residuals. For most veterans that means hypothyroidism, because a total thyroidectomy or radioiodine ablation removes the gland's function.
Here is the part that the guides get wrong. Current DC 7903 has exactly two levels.
100 percent. Hypothyroidism manifesting as myxedema, meaning cold intolerance, muscular weakness, cardiovascular involvement (including hypotension, bradycardia, and pericardial effusion), and mental disturbance (including dementia, slowing of thought, and depression). Note (1) continues this evaluation for six months beyond the date an examining physician determines crisis stabilization, after which residual effects are rated under the appropriate body-system codes.
30 percent. Hypothyroidism without myxedema. Note (2) reads: "This evaluation shall continue for six months after initial diagnosis. Thereafter, rate residuals of disease or medical treatment under the most appropriate diagnostic code(s) under the appropriate body system."
The 30 percent is a window, not a destination. It expires six months after the hypothyroidism is first diagnosed. Because the note counts from that initial diagnosis, not from the end of the DC 7914 rating, the window can run out while the DC 7914 100 percent is still in place when hypothyroidism is diagnosed soon after thyroidectomy. After that, VA rates whatever residual effects the record documents, each under its own code in its own body system. Eye, digestive, and mental disorders are the examples the regulation itself gives.
A veteran on well-controlled hormone replacement with no documented residual effects can therefore land at 0 percent for the thyroid itself. That is not an error by the rater. It is what the current criteria say. The older version of DC 7903, which rated hypothyroidism at 10, 30, 60, or 100 percent, was replaced by the endocrine amendment effective December 10, 2017. When VA adopted the change, it rejected a request to keep a 10 percent minimum for continuous medication, reasoning that medical management without symptoms does not impair earning capacity.
Thyroid cancer residuals worth documenting
Because the percentage after the windows close depends entirely on documented residual effects, the useful work happens before the examination, not after the decision. Thyroid surgery can damage the parathyroid glands or the recurrent laryngeal nerve, which controls the vocal cords, so look for both.
- Hypoparathyroidism. If the parathyroid glands were damaged or removed during thyroidectomy, DC 7905 applies. It assigns 100 percent for three months after initial diagnosis, then rates chronic residuals such as nephrolithiasis, cataracts, decreased renal function, and congestive heart failure under their own codes. Note the window here is three months, not six.
- Voice impairment. Recurrent laryngeal nerve injury during surgery causes hoarseness or vocal cord paralysis. Rate under the larynx codes in § 4.97, such as chronic laryngitis (DC 6516) for hoarseness or aphonia (DC 6519) for loss of voice, or under DC 8210 for the vagus nerve, whose rating the schedule ties to the loss affecting the organs of voice.
- Neck scarring. Surgical scars of the head, face, or neck are rated under DC 7800. This is separate from the endocrine evaluation. See the scars guide for the characteristics of disfigurement.
- Eye, digestive, and mental effects. These are the body systems DC 7903 names as examples for rating residual effects; heart findings go under the cardiovascular codes. Each needs a diagnosis and findings in the record, not just a symptom mentioned in passing.
Ask the endocrinologist to document specific measured effects early, before these windows close. A note that says "patient stable on levothyroxine" supports nothing after the window closes. A note that records documented cognitive slowing, a cardiac finding, or a measured calcium abnormality supports a rating under a code that has no expiration.
How to prove thyroid cancer is service connected
Thyroid cancer can be service connected through the PACT Act, two radiation routes, or a direct claim. The Agent Orange and Camp Lejeune presumptions do not cover it.
PACT Act: thyroid cancer as a neck cancer
Thyroid cancer is presumptive under the PACT Act for a covered veteran. The PACT Act presumption in 38 USC § 1120 lists "neck cancer of any type" among its cancers. Section 1119 defines a covered veteran by service, including the airspace above, on or after August 2, 1990 in Bahrain, Iraq, Kuwait, Oman, Qatar, Saudi Arabia, Somalia, or the United Arab Emirates, or on or after September 11, 2001 in Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Yemen, Uzbekistan, or another country the Secretary determines relevant.
The statute does not name the thyroid. VA's PACT Act claims guidance does: VBA Letter 20-22-10 (December 22, 2022) and its June 2024 update, VBA Letter 20-24-06, list thyroid cancer (anaplastic, papillary, follicular and medullary) among their examples of neck cancers. For a covered veteran, the link to service is presumed, subject to the rebuttal rules in 38 USC § 1113. The presumption does not set the percentage; DC 7914 and the residual codes still do.
Radiation-exposed veterans: 38 CFR § 3.309(d)
Thyroid cancer has two radiation pathways, and they work differently.
Cancer of the thyroid is listed at § 3.309(d)(2)(ii). If you participated in a radiation-risk activity as that term is defined at § 3.309(d)(3), the disease is presumed service connected, subject to § 3.307. No dose reconstruction and no nexus opinion are required.
The definition is narrow and worth reading rather than assuming. Radiation-risk activity means onsite participation in a test involving the atmospheric detonation of a nuclear device; the occupation of Hiroshima or Nagasaki by United States forces between August 6, 1945 and July 1, 1946; internment as a prisoner of war in Japan under comparable exposure conditions; certain service at named gaseous diffusion plants; certain service on Amchitka Island, Alaska, before January 1, 1974, tied to the underground nuclear tests there; service that would qualify a Department of Energy employee for the Special Exposure Cohort; cleanup of Enewetak Atoll from January 1, 1977 through December 31, 1980; and onsite response to the B-52 accidents near Palomares, Spain (January 17, 1966 through March 31, 1967) and Thule Air Force Base, Greenland (January 21 through September 25, 1968). Working near a radiation source in a general sense does not qualify.
Other radiation exposure: 38 CFR § 3.311
Thyroid cancer is listed as a radiogenic disease at 38 CFR § 3.311(b)(2)(ii). This route is for ionizing radiation exposure that does not meet the § 3.309(d) definition. VA must obtain a dose estimate and refer the claim for a causation opinion. That development is mandatory, so a decision that skips it is worth appealing on procedure alone.
Direct service connection
Under 38 CFR § 3.303, a thyroid nodule documented in service and later confirmed malignant can support direct service connection with a medical opinion on onset timing. Section 3.303(d) allows service connection for a disease first diagnosed after separation when the evidence establishes it was incurred in service.
Agent Orange and Camp Lejeune
Thyroid cancer is not on the Agent Orange list in 38 CFR § 3.309(e) or the Camp Lejeune list in § 3.309(f). A veteran whose only exposure is herbicide or Camp Lejeune water needs a direct claim with a medical opinion.
Why VA denies thyroid cancer claims
Thyroid cancer claims do better at the Board than the average claim. Across 563 decided Board rulings on thyroid cancer from 2021 to 2026, 31.3% were granted, 18.7% denied and 50.1% remanded. A ruling is one issue the Board decided in one decision; one decision often rules on several issues. That grant rate is 6.6 points above the Board-wide 24.7 percent, and about half of the decided rulings were remands.
The failure modes, on service connection and on the rating, are consistent.
- Relying on Agent Orange or Camp Lejeune, whose lists do not include thyroid cancer, or overlooking the PACT Act neck cancer presumption for a covered veteran.
- Assuming any radiation exposure meets the § 3.309(d) radiation-risk activity definition.
- Letting VA skip the § 3.311 dose estimate when § 3.309(d) does not apply.
- Assuming the 100 percent is permanent because the cancer was serious.
- Missing the mandatory six-month examination and treating the resulting reduction as final.
- Accepting a reduction that did not follow the § 3.105(e) notice procedure.
- Believing that a lifelong levothyroxine prescription holds a 30 percent rating.
- Letting the DC 7903 six-month window pass without documenting specific residual effects.
- Missing hypoparathyroidism, voice impairment, or neck scarring as separately ratable residuals.
When the Board sends a thyroid cancer claim back instead of deciding it, the most common reason is an inadequate VA exam or opinion, followed by records VA still had to get. The Board section below shows the remand reasons and how claims argued as direct and presumptive fared.
Questions veterans ask about thyroid cancer
What is the VA rating for thyroid cancer?
Thyroid cancer is rated 100 percent under DC 7914 while it is treated and for six months after treatment ends. A mandatory VA exam then sets the rating. If the cancer has not come back, the rating is based on residuals such as hypothyroidism, hypoparathyroidism, voice problems or a neck scar.
Is thyroid cancer presumptive under the PACT Act?
Yes, for a covered veteran. VA's PACT Act guidance treats thyroid cancer as a neck cancer, and 38 USC § 1120 presumes neck cancer of any type for veterans who served in the listed countries on or after August 2, 1990 or September 11, 2001.
Is thyroid cancer presumptive for Agent Orange?
No. Thyroid cancer is not on the Agent Orange list in 38 CFR § 3.309(e). Without another presumption, such as the PACT Act or the radiation list, the claim needs a medical opinion linking the cancer to service.
What is the VA rating for hypothyroidism after a thyroidectomy?
Under DC 7903, hypothyroidism without myxedema is rated 30 percent for six months after it is first diagnosed. After that, VA rates the residual effects under the codes for the body systems involved. Taking levothyroxine is not by itself a rating criterion.
Is thyroid cancer presumptive for radiation exposure?
Yes, for veterans who took part in a radiation-risk activity listed in 38 CFR § 3.309(d)(3), such as atmospheric nuclear testing or the occupation of Hiroshima or Nagasaki. Other veterans with documented in-service radiation exposure go through the dose review in § 3.311, which lists thyroid cancer as a radiogenic disease.
Can I get a separate VA rating for a thyroidectomy scar?
Yes. A surgical scar on the neck is rated under DC 7800, separately from the cancer and hypothyroidism ratings. One characteristic of disfigurement, such as a scar at least a quarter inch wide or at least 5 inches long, supports 10 percent.
Bottom Line
Thyroid cancer pays 100 percent while it is being treated and for six months afterward. What you hold after that depends on what the record documents, not on what you take daily. The two six-month windows, one under DC 7914 and one under DC 7903, are the whole game for the rating. Use them to build a residual-by-residual record under codes that do not expire, and check whether the PACT Act neck cancer presumption or a radiation route applies to your service before you rely on a direct nexus opinion.
Related Conditions and Tools
Compare hypothyroidism, hyperthyroidism, and scars. Review DC 7903 for the residual code you are most likely to be rated under, and organize treatment records and residual findings with the Statement Builder and the C&P Exam Prep tool. To check which presumptions your service supports, use the presumptive conditions tool.
Sources and limits
Legal sources: 38 CFR § 4.119, § 3.309, § 3.311, § 3.105, and § 3.303, with 38 CFR §§ 4.97, 4.118 and 4.124a for the voice and scar codes, checked against the eCFR text in force on October 1, 2026. The 2017 endocrine amendment is 82 FR 50802 (effective December 10, 2017); the prior four DC 7903 levels are described in the proposed rule, 80 FR 39011 (2015). The PACT Act presumption is 38 USC §§ 1119 and 1120, and the thyroid cancer examples come from VBA Letter 20-22-10 (December 22, 2022) and VBA Letter 20-24-06 (June 12, 2024). Surgical complications are from Chen and Yuan, "Endocrine and neurological complications in total versus completion thyroidectomy," BMC Endocrine Disorders (2026), and Simon and colleagues, "The impact of surgery type on the recovery of iatrogenic vocal fold injury," European Archives of Oto-Rhino-Laryngology (2026), read as PubMed abstracts. Board figures come from Claim Raven's read of 510,968 Board decisions from 2021 to 2026, which contain 1,376,193 rulings, including 611 rulings on thyroid cancer; dismissed, withdrawn and moot rulings are excluded from the shares. These describe appealed claims, not your personal odds. Claim Raven is data analysis, not legal, medical, or VA-accredited advice.
